Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 05/11/17 → 03/22/19 |
Funding
- INC Research Incorporated: $10,500.00
Genentech: Phase III, Multicenter, Randomized, Placebo-Controlled Double-Blind Study of Atezoluzumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
- Wu, Shenhong (CoPI)
- Fitzgerald, John (PI)
- Zhang, Yue (CoPI)
Project: Research